To the Editor: We agree that the "what", "how" and "who" of guideline development all deserve equal, explicit and systematic attention.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Correspondence: nswtag@stvincents.com.au
- 1. Van der Weyden M. Clinical practice guidelines: time to move the debate from the how to the who [editorial]. Med J Aust 2002; 176: 304-305. <MJA full text>
- 2. Edmonds JP, Day RO, Bertouch JV. The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors. Med J Aust 2002; 176: 332-334. <MJA full text>
- 3. Current Opinion: Cox-2 inhibitors — the evidence. Darlinghurst: NSW Therapeutic Assessment Group, January 2001. Available at <http://www.clininfo.health.nsw.gov.au/nswtag/publications/posstats/COX%202.pdf>.
- 4. National Health and Medical Research Council. Guidelines for the development and implementation of clinical practice guidelines. Canberra: AGPS, 1995.
- 5. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000; 283: 373-380.
- 6. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612-617.
Online responses are no longer available. Please refer to our instructions for authors page for more information.